SBT-272 Phase 1 safety and tolerability data support further clinical development
SBT-272 was neuroprotective and reduced neuroinflammation in ALS preclinical model
Read more at prnewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
SBT-272 Phase 1 safety and tolerability data support further clinical development
SBT-272 was neuroprotective and reduced neuroinflammation in ALS preclinical model
Read more at prnewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| MITO | 0.3200 | -0.0044 | -1.36% |
| Stealth Biotherapeutics Corp ADR | |||